Humacyte, Inc. (HUMA) stock

HUMANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 10, 2026Score 2/30

$0.60+0.00 (+0.63%)

Close on Nov 12, 2026Market cap $165.40MP/E –Yield –

Humacyte price to book ratio

The price-to-book ratio is market cap divided by shareholders' equity.

Humacyte's price to book ratio was 5.3× on Nov 11, 2026, against 59.8× a year earlier. Over the last 4 years it ranged from 1.8× to 69.2×, with a median of 6.5×.

Price to Book Ratio at the end of each year

Period	Period end	Value	Change (pts)
2026	Nov 11, 2026	5.3×	−59.2
2025	Oct 31, 2025	64.4×	+21.4
2024	Jul 31, 2024	43.1×	+35.1
2023	Dec 29, 2023	7.9×	+6.1
2022	Dec 30, 2022	1.8×	−8.0
2021	Dec 31, 2021	9.8×	–

Where these numbers come from

Parsed from the XBRL in Humacyte's annual and quarterly filings with the SEC
Per-share figures adjusted for the 2-for-1 split on Nov 15, 2021
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is HUMA.

Compare: HUMA vs DYAI · HUMA vs PROK · HUMA vs PRME · HUMA vs PLUR · HUMA vs ATRA

Revenue growth52.5% · median -1.9%

Gross margin-475.1% · median 34.1%

Operating margin-4602.9% · median -1342.3%

Net margin-3955.1% · median -1156.2%

Company	Revenue	Growth
ATRA	$3.97M	-97.4%
DYAI	$3.80M	-8.0%
HUMA	$2.40M	+52.5%
PLUR	$1.46M	+10.0%
PROK	$775.00K	+4.2%
PRME	–	–

Company

Next earnings (est.): Mar 18, 2027, before open
Exchange: Nasdaq
Industry: Biological Products, (No Diagnostic Substances)
Fiscal year ends: December 31
Employees: 184
Held by institutions: 26.4%
Auditor: PricewaterhouseCoopers LLP
SEC CIK: 1818382

Advertisement
300 × 250

See a number that looks wrong?